Daniel R. Omstead's most recent trade in Tekla Life Sciences Investors was a trade of 10,096 Shares of Beneficial Interest done at an average price of $12.4 . Disclosure was reported to the exchange on Sept. 25, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tekla Life Sciences Investors | Daniel R. Omstead | Director, President | 25 Sep 2023 | 10,096 | 197,518 (0%) | 0% | 12.4 | 125,116 | Shares of Beneficial Interest | |
| Tekla Healthcare Investors | Daniel R. Omstead | Director, President | Purchase of securities on an exchange or from another person at price $ 15.63 per share. | 25 Sep 2023 | 9,500 | 178,268 (0%) | 0% | 15.6 | 148,515 | Shares of Beneficial Interest |
| Tekla Life Sciences Investors | Daniel R. Omstead | Director, President | 20 Sep 2023 | 12,000 | 187,422 (0%) | 0% | 12.7 | 152,206 | Shares of Beneficial Interest | |
| Tekla Healthcare Investors | Daniel R. Omstead | Director, President | Purchase of securities on an exchange or from another person at price $ 15.88 per share. | 20 Sep 2023 | 9,500 | 168,768 (0%) | 0% | 15.9 | 150,829 | Shares of Beneficial Interest |
| Tekla Life Sciences Investors | Daniel R. Omstead | Director, President | 11 Aug 2021 | 6,403 | 146,489 (0%) | 0% | 21.6 | 138,497 | Shares of Beneficial Interest |